TITLE

Multiple myeloma and related conditions

AUTHOR(S)

Singer, Charles R J

PUB. DATE

March 1997

SOURCE

BMJ: British Medical Journal (International Edition);03/29/97, Vol. 314 Issue 7085, p960

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Features the treatment of multiple myeloma. Clinical features; Investigations and diagnosis; Conditions associated with M proteins; Minimal diagnostic criteria; Management and clinical course.

ACCESSION #

9704292302

 

Related Articles

• LETTER FROM THE EDITOR-IN-CHIEF. Lonial, Sagar // Personalized Medicine in Oncology;Feb2014, Vol. 3 Issue 1, p24 

  No abstract available.

• The Myeloma Survival Guide. Faiman, Beth // Oncology Nurse-APN/PA;Sep/Oct2014, Vol. 7 Issue 5, p19 

  No abstract available.

• Expert comment. Lobban, Lois // Nursing Standard;5/28/2014, Vol. 28 Issue 39, p18 

  In this article the author offers her opinions on the treatment of patients with multiple myeloma.

• Multiple myeloma incidence. Harras, Angela // JNCI: Journal of the National Cancer Institute;1/05/94, Vol. 86 Issue 1, p9 

  Presents a graph showing the incidence of multiple myeloma in Americans in 1993. Prognosis; Genetic and environmental links.

• International uniform response criteria for multiple myeloma. Durie, B G M; Harousseau, J-L; Miguel, J S; Bladé, J; Barlogie, B; Anderson, K; Gertz, M; Dimopoulos, M; Westin, J; Sonneveld, P; Ludwig, H; Gahrton, G; Beksac, M; Crowley, J; Belch, A; Boccadaro, M; Turesson, I; Joshua, D; Vesole, D; Kyle, R // Leukemia (08876924);Dec2006, Vol. 20 Issue 12, p2220 

  A correction to the article "International Uniform Response Criteria for Multiple Myeloma" that was published in a previous issue is presented.

• Erratum to: pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients. Buda, Gabriele; Orciuolo, Enrico; Galimberti, Sara; Pelosini, Matteo; Petrini, Mario // Annals of Hematology;Jul2011, Vol. 90 Issue 7, p863 

  A correction to the article "Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients," that was published in the previous issue is presented.

• International uniform response criteria for multiple myeloma. Durie1, B G M; Harousseau2, J-L; Miguel3, J S; Bladé4, J; Barlogie5, B; Anderson6, K; Gertz7, M; Dimopoulos8, M; Westin9, J; Sonneveld10, P; Ludwig11, H; Gahrton12, G; Beksac13, M; Crowley14, J; Belch15, A; Boccadaro16, M; Turesson17, I; Joshua18, D; Vesole19, D; Kyle7, R // Leukemia (08876924);May2007, Vol. 21 Issue 5, p1134 

  A correction to the article about multiple myeloma that was published in the 2006 issue is presented.

• Expression and mutation status of candidate kinases in multiple myeloma. Claudio, J. O.; Zhan, F.; Zhuang, L.; Khaja, R.; Zhu, Y. X.; Sivananthan, K.; Trudel, S.; Masih-Khan, E.; Fonseca, R.; Bergsagel, P. L.; Scherer, S. W.; Shaughnessy, J.; Stewart, A. K. // Leukemia (08876924);Apr2008, Vol. 22 Issue 4, p889 

  A correction to the article "Expression and mutation status of candidate kinases in multiple myeloma" that was published in the May 2007 issue is presented.

• Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. Jakob, C.; Sterz, J.; Liebisch, P.; Mieth, M.; Rademacher, J.; Goerke, A.; Heider, U.; Fleissner, C.; Kaiser, M.; von Metzler, I.; Müller, C.; Sezer, O. // Leukemia (08876924);Sep2008, Vol. 22 Issue 9, p1812 

  A correction to the article "Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma" is presented.

Read the Article